No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine

  • Van Vugt M
  • Ezzet F
  • Nosten F
 et al. 
  • 45


    Mendeley users who have this article in their library.
  • 66


    Citations of this article.


Artemether-lumefantrine is a new fixed antimalarial combination effective against multidrug-resistant falciparum malaria. A prospective electrocardiographic study was conducted in 150 patients receiving artemetherlumefantrine and 50 treated with artesunate-mefloquine. There was no evidence for clinically significant changes in the electrocardiographic intervals and in particular no relationship between plasma concentrations of lumefantrine and QTc prolongation. Artemether-lumefantrine does not have significant cardiac effects at therapeutic doses.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • M. Van Vugt

  • F. Ezzet

  • F. Nosten

  • I. Gathmann

  • P. Wilairatana

  • S. Looareesuwan

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free